Development of functionally selective, small molecule agonists at kappa opioid receptors

Area of Science:

• Neuroscience and Pharmacology
• G protein-coupled receptor (GPCR) signaling

Background:

• The kappa opioid receptor (KOR) is a key target for treating pain, depression, and addiction due to its role in the central nervous system (CNS).
• KOR agonists can activate distinct signaling pathways, including G protein coupling and βarrestin2 recruitment, leading to varied physiological effects like analgesia and dysphoria.
• The dysphoria induced by KOR activation limits its therapeutic use, necessitating the development of biased agonists.

Purpose of the Study:

• To design and characterize novel kappa opioid receptor (KOR) agonists with biased signaling profiles.
• To develop compounds that preferentially activate G protein coupling over βarrestin2 recruitment.
• To explore the therapeutic potential of functionally selective KOR agonists for pain management.

Main Methods:

• Synthesis and characterization of two distinct classes of small molecule KOR agonists.
• Assessment of agonist potency in activating G protein coupling.
• Evaluation of agonist efficacy in recruiting βarrestin2.
• In vivo studies to assess the therapeutic potential of biased KOR agonists.

Main Results:

• Identified two novel classes of KOR agonists demonstrating potent G protein activation.
• These biased agonists exhibited significantly reduced βarrestin2 recruitment compared to traditional agonists.
• The developed compounds are potent and functionally selective, offering a refined approach to KOR-directed signaling.

Conclusions:

• Biased KOR agonists that favor G protein coupling over βarrestin2 recruitment can be developed.
• These selective compounds hold promise for mitigating KOR-mediated dysphoria while retaining analgesic effects.
• The identified small molecules serve as valuable tools for further investigation into KOR signaling pathways and therapeutic applications.